Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BNTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BNTX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

1.66 %
Forward Annual Dividend Yield
Consecutive Years 0
Forward Annual Dividend – USD
Consistent Years 0
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date 02.06.2022

BioNTech SE

BNTX
Current price
111.78 USD -0.02 USD (-0.02%)
Last closed 111.66 USD
ISIN US09075V1026
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 26 443 450 368 USD
Yield for 12 month +37.49 %
1Y
3Y
5Y
10Y
15Y
BNTX
21.11.2021 - 28.11.2021

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. Address: An der Goldgrube 12, Mainz, Germany, 55131

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

137.60 USD

P/E Ratio

Dividend Yield

Financials BNTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BNTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+3 237 064 274 USD

Last Year

+4 493 602 000 USD

Current Quarter

+215 090 454 USD

Last Quarter

+1 400 205 913 USD

Current Year

+2 600 147 080 USD

Last Year

+3 787 851 155 USD

Current Quarter

+116 487 719 USD

Last Quarter

+1 113 693 190 USD
EBITDA -1 019 900 032 USD
Operating Margin TTM -270.46 %
Price to Earnings
Return On Assets TTM -3.67 %
PEG Ratio 0.045
Return On Equity TTM -3.94 %
Wall Street Target Price 137.60 USD
Revenue TTM 2 746 299 904 USD
Book Value 78.73 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -2.60 %
Dividend Yield
Gross Profit TTM 2 180 300 032 USD
Earnings per share -3.76 USD
Diluted Eps TTM -3.76 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -43.20 %
Profit Margin -27.89 %

Stock Valuation BNTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 7.04
Enterprise Value Revenue 3.13
Price Sales TTM 9.63
Enterprise Value EBITDA 110.81
Price Book MRQ 1.18

Technical Indicators BNTX

For 52 Weeks

76.53 USD 131.49 USD
50 Day MA 103.24 USD
Shares Short Prior Month 5 201 471
200 Day MA 109.50 USD
Short Ratio 5.04
Shares Short 6 108 557
Short Percent 6.62 %